|
1
|
Raman JD, Messer J, Sielatycki JA and
Hollenbeak CS: Incidence and survival of patients with carcinoma of
the ureter and renal pelvis in the USA, 1973–2005. BJU Int.
107:1059–1064. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chou YH and Huang CH: Unusual clinical
presentation of upper urothelial carcinoma in Taiwan. Cancer.
85:1342–1344. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rouprêt M, Babjuk M, Compérat E, Zigeuner
R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW,
Kaasinen E, et al: European association of urology guidelines on
upper urinary tract urothelial cell carcinoma: 2015 Update. Eur
Urol. 68:868–879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Margulis V, Youssef RF, Karakiewicz PI,
Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi
M, et al: Preoperative multivariable prognostic model for
prediction of nonorgan confined urothelial carcinoma of the upper
urinary tract. J Urol. 184:453–458. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang MH, Chen KK, Yen CC, Wang WS, Chang
YH, Huang WJS, Fan FS, Chiou TJ, Liu JH and Chen PM: Unusually high
incidence of upper urinary tract urothelial carcinoma in Taiwan.
Urology. 59:681–68. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liao RS, Gupta M, Schwen ZR, Patel HD,
Kates M, Johnson MH, Hahn NM, McConkey D, Bivalacqua TJ and
Pierorazio PM: Comparison of pathological stage in patients treated
with and without neoadjuvant chemotherapy for high risk upper tract
urothelial carcinoma. J Urol. 200:68–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leow JJ, Chong YL, Chang SL, Valderrama
BP, Powles T and Bellmunt J: Neoadjuvant and adjuvant chemotherapy
for upper tract urothelial carcinoma: A 2020 systematic review and
meta-analysis, and future perspectives on systemic therapy. Eur
Urol. 79:635–654. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stangl-Kremser J, Muto G, Grosso AA,
Briganti A, Comperat E, Di Maida F, Montironi R, Remzi M, Pradere
B, Soria F, et al: The impact of lymphovascular invasion in
patients treated with radical nephroureterectomy for upper tract
urothelial carcinoma: An extensive updated systematic review and
meta-analysis. Urol Oncol. 40:243–261. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Birtle A, Johnson M, Chester J, Jones R,
Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto
JWF, et al: Adjuvant chemotherapy in upper tract urothelial
carcinoma (the POUT trial): A phase 3, open-label, randomised
controlled trial. Lancet. 395:1268–1277. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chromecki TF, Cha EK, Fajkovic H, Margulis
V, Novara G, Scherr DS, Lotan Y, Raman JD, Kassouf W, Bensalah K,
et al: The impact of tumor multifocality on outcomes in patients
treated with radical nephroureterectomy. Eur Urol. 61:245–253.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zou L, Zhang L, Zhang H, Jiang H and Ding
Q: Comparison of post-operative intravesical recurrence and
oncological outcomes after open versus laparoscopic
nephroureterectomy for upper urinary tract urothelial carcinoma.
World J Urol. 32:565–570. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fang D, Xiong GY, Li XS, Chen XP, Zhang L,
Yao L, He ZS and Zhou LQ: Pattern and risk factors of intravesical
recurrence after nephroureterectomy for upper tract urothelial
carcinoma: A large Chinese center experience. J Formos Med Assoc.
113:820–827. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ouzzane A, Colin P, Xylinas E, Pignot G,
Ariane MM, Saint F, Hoarau N, Adam E, Azemar MD, Bensadoun H, et
al: Ureteral and multifocal tumours have worse prognosis than renal
pelvic tumours in urothelial carcinoma of the upper urinary tract
treated by nephroureterectomy. Eur Urol. 60:1258–1265. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Williams AK, Kassouf W, Chin J, Rendon R,
Jacobsen N, Fairey A, Kapoor A, Black P, Lacombe L, Tanguay S, et
al: Multifocality rather than tumor location is a prognostic factor
in upper tract urothelial carcinoma. Urol Oncol. 31:1161–1165.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen CS, Li JR, Wang SS, Yang CK, Cheng
CL, Yang CR, Ou YC, Ho HC, Lin CY, Hung SC, et al: Tumor
multifocality is a significant risk factor of urinary bladder
recurrence after nephroureterectomy in patients with upper tract
urothelial carcinoma: A single-institutional study. Diagnostics
(Basel). 10:2012020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Milojevic B, Bumbasirevic U, Santric V,
Kajmakovic B, Dragicevic D, Radisavcevic D, Sretenovic M and
Grujicic SS: Prognostic significance of tumor multifocality on
outcomes in patients with upper tract urothelial carcinoma after
radical nephroureterectomy: A cohort study. Curr Probl Cancer.
45:1007472021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sheu ZL, Huang CP, Chang CH, Chen CH, Hong
JH, Weng HY, Tai TY, Chung SD, Lo CW, Hsueh TY, et al: Tumor
distribution affects bladder recurrence but not survival outcome of
multifocal upper tract urothelial carcinoma treated with radical
nephroureterectomy. Sci Rep. 11:190592021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nøst TH, Alcala K, Urbarova I, Byrne KS,
Guida F, Sandanger TM and Johansson M: Systemic inflammation
markers and cancer incidence in the UK Biobank. Eur J Epidemiol.
36:841–848. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou Q, Su S, You W, Wang T, Ren T and Zhu
L: Systemic inflammation response index as a prognostic marker in
cancer patients: A systematic review and meta-analysis of 38
cohorts. Dose Response. 19:155932582110647442021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chao B, Ju X, Zhang L, Xu X and Zhao Y: A
novel prognostic marker systemic inflammation response index (SIRI)
for operable cervical cancer patients. Front Oncol. 10:7662020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang T, Zhang D, Tang D, Heng Y, Lu LM and
Tao L: The role of systemic inflammatory response index (SIRI) and
tumor-infiltrating lymphocytes (TILs) in the prognosis of patients
with laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol.
149:5627–5636. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Zhou Y, Xia S, Lu L, Dai T, Li A,
Chen Y and Gao E: Prognostic value of the systemic inflammation
response index (SIRI) before and after surgery in operable breast
cancer patients. Cancer Biomark. 28:537–547. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Min L, Ziyu D, Xiaofei Z, Shunhe X and
Bolin W: Analysis of levels and clinical value of CA19-9, NLR and
SIRI in patients with pancreatic cancer with different clinical
features. Cell Mol Biol (Noisy-le-grand). 67:302–308. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jan HC, Yang WH and Ou CH: Combination of
the preoperative systemic immune-inflammation index and
monocyte-lymphocyte ratio as a novel prognostic factor in patients
with upper-tract urothelial carcinoma. Ann Surg Oncol. 26:669–684.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chien TM, Li CC, Lu YM, Chou YH, Chang HW
and Wu WJ: The predictive value of systemic immune-inflammation
index on bladder recurrence on upper tract urothelial carcinoma
outcomes after radical nephroureterectomy. J Clin Med. 10:52732021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng Y, Chen Y, Chen J, Chen W, Pan Y,
Bao L and Gao X: Combination of systemic inflammation response
index and platelet-to-lymphocyte ratio as a novel prognostic marker
of upper tract urothelial carcinoma after radical
nephroureterectomy. Front Oncol. 9:9142019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eble JN, Sauter G, Epstein J and
Sesterhenn I: Pathology and genetics of tumours of the urinary
system and male genital organs. WHO Classification of Tumours. Vol
7. 3rd edition. IARC; 2004
|
|
29
|
Pacheco-Barcia V, Mondéjar Solis R, France
T, Asselah J, Donnay O, Zogopoulos G, Bouganim N, Guo K, Rogado J,
Martin E, et al: A systemic inflammation response index (SIRI)
correlates with survival and predicts oncological outcome for
mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology.
20:254–264. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McFarland DC, Doherty M, Atkinson TM,
O'Hanlon R, Breitbart W, Nelson CJ and Miller AH: Cancer-related
inflammation and depressive symptoms: Systematic review and
meta-analysis. Cancer. 128:2504–2519. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moses K and Brandau S: Human neutrophils:
Their role in cancer and relation to myeloid-derived suppressor
cells. Semin Immunol. 28:187–196. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mori K, Resch I, Miura N, Laukhtina E,
Schuettfort VM, Pradere B, Katayama S, D'Andrea D, Kardoust Parizi
M, Abufaraj M, et al: Prognostic role of the systemic
immune-inflammation index in upper tract urothelial carcinoma
treated with radical nephroureterectomy: Results from a large
multicenter international collaboration. Cancer Immunol Immunother.
70:2641–2650. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang C, Wang M, Chen L, Wang H, Huang D,
Shi J, Zhang W, Tian Y and Zhu Y: The pretherapeutic systemic
inflammation score is a prognostic predictor for elderly patients
with oesophageal cancer: A case control study. BMC Cancer.
23:5052023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bruno M, Bizzarri N, Teodorico E, Certelli
C, Gallotta V, Pedone Anchora L, Fagotti A, Fanfani F, Scambia G
and Ferrandina G: The potential role of systemic inflammatory
markers in predicting recurrence in early-stage cervical cancer.
Eur J Surg Oncol. 50:1073112024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hamilton G, Rath B, Klameth L and Hochmair
MJ: Small cell lung cancer: Recruitment of macrophages by
circulating tumor cells. Oncoimmunology. 5:e10932772015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim J and Bae JS: Tumor-associated
macrophages and neutrophils in tumor microenvironment. Mediators
Inflamm. 2016:60581472016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
